Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Ohio state sits at the center of this dementia and brain health question.
Ohio State University researchers have released significant findings showing that long-term benzodiazepine use is associated with a 51 percent higher risk of developing dementia later in life. This research adds to growing evidence that while benzodiazepines like Valium, Xanax, and Ativan are effective for short-term anxiety and sleep problems, their extended use—particularly over years or decades—may carry substantial neurological risks that many patients and doctors don’t fully discuss. The study examined medical records and brain health outcomes over extended periods, finding that individuals who took these medications regularly faced substantially elevated dementia risk compared to those who didn’t use them.
The implications are particularly serious because benzodiazepines remain among the most commonly prescribed medications in the United States, with millions of older adults taking them for anxiety, insomnia, or muscle tension. A patient who started taking Xanax for panic attacks in their 50s and continued for 20 years without reassessing the medication’s necessity faces a fundamentally different risk profile than someone who used the same drug for two weeks to manage acute stress. Understanding this research is critical for anyone currently taking these medications, as well as for their family members and doctors who may need to reconsider long-term treatment plans.
Table of Contents
- Why Do Benzodiazepines Increase Dementia Risk?
- The Dose and Duration Matter in Benzodiazepine’s Brain Effects
- What Happens When You Stop Benzodiazepines After Long-Term Use?
- Managing Anxiety and Sleep Without Long-Term Benzodiazepines
- Older Adults Face Particular Benzodiazepine Risks
- The Role of Underlying Anxiety and Stress Conditions
- Future Research and Clinical Practice Changes
- Conclusion
- Frequently Asked Questions
Why Do Benzodiazepines Increase Dementia Risk?
The exact biological mechanisms behind the increased dementia risk aren’t fully understood, but researchers point to several plausible explanations. Benzodiazepines work by enhancing the brain’s GABA neurotransmitter, which suppresses neural activity and produces a calming effect. However, prolonged exposure to this chemical depression of brain activity may interfere with normal cognitive processes and neuroplasticity—the brain’s ability to form new connections and retain information. When the brain is chronically depressed by sedating medications, it may struggle to maintain the neural networks essential for memory formation and retrieval.
Additionally, benzodiazepines increase the risk of falls, which can lead to head injuries in older adults. A single serious fall causing traumatic brain injury could set a person on a path toward cognitive decline. Beyond direct mechanisms, long-term benzodiazepine use is associated with chronic sedation, reduced cognitive engagement, and social withdrawal—all factors that independently increase dementia risk. A 75-year-old taking daily Valium for 15 years might spend those years less mentally stimulated than peers without the medication, potentially accelerating cognitive aging even without direct chemical damage to brain tissue.
The Dose and Duration Matter in Benzodiazepine’s Brain Effects
The Ohio State research found that risk didn’t increase uniformly—longer duration of use and higher doses carried greater dementia risk. Someone who took a benzodiazepine sporadically for a few months faced minimal additional risk, while someone on regular doses for multiple years showed substantially elevated risk. This dose-duration relationship is critical because it contradicts the sometimes casual attitude toward “occasional” benzodiazepine use. A patient who says “I only take it when I need it” might actually be taking it several times weekly over years, accumulating significant exposure.
However, an important limitation of this research is that it shows correlation, not definitive causation. People prescribed long-term benzodiazepines may differ from the general population in ways that independently increase dementia risk—they may have higher stress levels, underlying neurological conditions, or other health factors that led to the benzodiazepine prescription in the first place. Untangling whether the medication itself causes dementia or whether people with certain risk factors are simply more likely to receive benzodiazepines long-term requires careful analysis. Nevertheless, the strength and consistency of the association across multiple studies suggests the medication itself likely contributes to the increased risk rather than merely indicating who is at risk.
What Happens When You Stop Benzodiazepines After Long-Term Use?
For people who have been taking benzodiazepines for years, the question of whether to stop is complicated by physical dependence and withdrawal. The brain adapts to chronic benzodiazepine use, and abrupt cessation can trigger severe withdrawal symptoms including seizures, which themselves carry neurological risks. A patient who has been on Ativan daily for a decade cannot simply stop taking it; the discontinuation must be carefully managed with gradual dose reductions over weeks or months, often requiring medical supervision.
The encouraging finding from recent research is that some cognitive improvements have been observed in older adults who successfully discontinued long-term benzodiazepines, even after decades of use. Memory function and processing speed sometimes improve months after stopping, suggesting that some of the cognitive damage is reversible. However, this shouldn’t be interpreted as complete recovery—there may be permanent effects, particularly in people who used the medications during critical periods of cognitive development or in those with existing cognitive decline. For someone in their 80s who has taken a benzodiazepine for 30 years, the decision to discontinue must weigh the dementia risk against the very real possibility of uncontrollable anxiety, insomnia, and potentially dangerous withdrawal symptoms.
Managing Anxiety and Sleep Without Long-Term Benzodiazepines
The most practical response to the Ohio State findings is to recognize that benzodiazepines should rarely be a long-term solution, even though many patients and doctors treat them that way. Cognitive behavioral therapy for insomnia (CBT-I) and cognitive behavioral therapy for anxiety (CBT-A) have strong evidence supporting their effectiveness and produce lasting improvements without the dementia risk. A patient struggling with insomnia might spend eight weeks with a therapist learning sleep restriction, stimulus control, and cognitive techniques that actually address the root problem rather than temporarily suppressing it with medication. Comparison: A 65-year-old with chronic anxiety has two main options.
Path A involves starting a benzodiazepine, feeling relief within hours, but then finding they need it indefinitely and watching their dementia risk climb by 51 percent. Path B involves working with a therapist on CBT-A, experiencing gradual improvement over 8-12 weeks, achieving lasting anxiety reduction without medication, and maintaining normal dementia risk. The second path requires more upfront effort but avoids the decades-long dependency and health risks. Other options including SSRIs, buspirone, and non-pharmacological approaches like meditation, exercise, and sleep hygiene modifications should be tried before or instead of long-term benzodiazepines.
Older Adults Face Particular Benzodiazepine Risks
The concern about benzodiazepines is most acute in older adults, who metabolize medications differently than younger people and are already at elevated dementia risk due to aging. The American Geriatrics Society has long recommended against benzodiazepines in adults over 65, citing both the dementia risk and the increased fall risk in this population. Yet despite this clear guidance, benzodiazepines remain frequently prescribed to older adults, sometimes because the doctor initiated the medication years earlier and neither patient nor doctor reassessed whether it’s still necessary. A critical warning: Many older adults are essentially trapped in benzodiazepine use.
They started taking the medication in their 50s or 60s for a legitimate problem, became physically dependent, and now cannot stop without severe withdrawal symptoms. Their neurologist tells them the medication increases dementia risk, but their anxiety is severe without it, and they fear the withdrawal process. This situation is unfortunately common and highlights why preventing long-term benzodiazepine use in the first place is so important. Doctors should be prescribing these medications with explicit time limits and regular reassessment, not as open-ended solutions.
The Role of Underlying Anxiety and Stress Conditions
It’s important to recognize that the increased dementia risk from benzodiazepines doesn’t mean anxiety disorder itself doesn’t increase dementia risk. Chronic stress and untreated anxiety are independent risk factors for cognitive decline. The goal isn’t simply to avoid benzodiazepines but to find effective treatment for the underlying anxiety.
Someone who treats their anxiety disorder with therapy, exercise, and selective serotonin reuptake inhibitor medications shows better long-term outcomes than someone who treats it with benzodiazepines. The complexity lies in severe anxiety disorders that don’t respond well to standard treatment. A patient with panic disorder who has tried multiple SSRIs and therapy without adequate relief may genuinely need benzodiazepines. The key in these cases is to use the lowest effective dose, combine it with ongoing attempts at therapy and other treatments, and regularly reassess whether continued use is justified—not to accept indefinite benzodiazepine dependence as inevitable.
Future Research and Clinical Practice Changes
The Ohio State findings are part of a broader shift in how the medical community views benzodiazepines. Multiple studies from different institutions have replicated similar findings, strengthening the evidence that long-term use carries dementia risk. This growing body of research is beginning to change prescribing practices, with more doctors implementing benzodiazepine-tapering programs and avoiding initial prescriptions when possible.
Insurance companies are also beginning to require justification for long-term benzodiazepine prescriptions, creating external pressure for dose reductions and medication switches. Looking forward, the challenge is addressing the millions of people already on long-term benzodiazepines who face the difficult choice between continuing a dementia-risk medication and undertaking a careful but uncomfortable discontinuation process. Specialized benzodiazepine-tapering clinics and programs are emerging in some areas, providing medical supervision and psychological support during the discontinuation process. As these programs expand and doctors become more skilled at managing benzodiazepine withdrawal, the option to discontinue becomes more feasible even after decades of use.
Conclusion
The Ohio State research demonstrating a 51 percent increased dementia risk with long-term benzodiazepine use represents an important clinical finding that should prompt serious conversations between patients and their doctors. Benzodiazepines remain valuable medications for acute anxiety and insomnia, but their role in long-term management needs to be reconsidered. The evidence increasingly suggests that continued benzodiazepine use for years or decades carries unacceptable neurological risks, particularly in older adults already vulnerable to dementia.
If you’re currently taking a benzodiazepine, the first step is to have an honest conversation with your doctor about how long you’ve been on it and whether the original reasons for starting it still apply. For many people, an honest reassessment reveals that the medication was started for a temporary problem that resolved years ago, yet the medication continued out of habit or because nobody questioned it. Exploring alternatives—including therapy, different medications, lifestyle modifications, and supervised discontinuation if you decide to stop—may provide better long-term outcomes for both your mental health and your cognitive health.
Frequently Asked Questions
Does every person on a benzodiazepine develop dementia?
No. The Ohio State research found that long-term users have a 51 percent increased risk—meaning higher probability—but many long-term users never develop dementia. However, because dementia risk is already substantial with aging, increasing that risk by 51 percent is clinically significant.
Is it safe to stop a benzodiazepine I’ve been taking for 10 years?
Stopping abruptly is not safe and can cause dangerous withdrawal symptoms including seizures. However, gradual discontinuation under medical supervision is often safe and may actually improve cognitive function. Your doctor should design a slow tapering schedule over weeks or months.
Can I switch from a benzodiazepine to an SSRI instead?
In many cases, yes. SSRIs treat anxiety without the dementia risk. However, the switch must be done carefully to avoid withdrawal symptoms from the benzodiazepine. Your doctor might overlap the medications briefly during the transition.
What’s the difference between short-term and long-term benzodiazepine use?
Short-term typically means a few weeks to a few months, which carries minimal dementia risk. Long-term typically means continuous use for over a year, with greater risk increasing substantially after several years of regular use.
If I have severe anxiety that’s hard to treat, should I take a benzodiazepine?
It’s reasonable to use benzodiazepines for acute anxiety while pursuing other treatments like therapy or different medications. The risk comes from indefinite long-term use, not from using them for a defined period while you work on other approaches.
Are all benzodiazepines equally risky for dementia?
The research doesn’t consistently show major differences between benzodiazepine types, though longer-acting medications might carry slightly higher risk due to their cumulative effect on the brain. The main risk factor is duration and dose of use rather than the specific drug.
You Might Also Like
- University of Iowa Researchers Link Chronic Pain to 43 Percent Higher Dementia Risk
- Mayo Clinic Researchers Link Common Heartburn Drug to 44 Percent Higher Dementia Risk
- Brown University Researchers Link Loneliness to 50 Percent Higher Dementia Risk
For more, see Alzheimer’s Association — clinical trials.
